Histogenics Corporation 2018 Form 10-K Summary
Filing identity: The supplied filing is for Histogenics Corporation, not Ocugen, Inc. It reports the fiscal year ended December 31, 2018 and was filed March 21, 2019. Histogenics was a clinical-stage regenerative medicine company focused primarily on NeoCart, an autologous cell therapy for knee cartilage damage.
Business Context and Reporting Period
- NeoCart was the company’s lead product and was being developed under a restorative cell therapy platform involving cell processing, scaffolds, tissue engineering and bioadhesives.
- In 2018, the Phase 3 NeoCart trial failed to meet its primary and secondary endpoints in the company’s principal analysis.
- Following FDA feedback in December 2018, management discontinued NeoCart development and stated that it did not plan to submit a Biologics License Application.
- Management shifted to evaluating strategic alternatives, including a sale of assets or intellectual property, merger, acquisition, joint venture, financing, recapitalization, wind-down or Chapter 11 bankruptcy.
Financial Metrics
| Metric | 2018 | 2017 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $15.6 million | $15.6 million | Approximately flat |
| General and administrative expense | $10.2 million | $9.4 million | Up $0.8 million |
| Asset impairment loss | $4.3 million | $0 | New charge |
| Loss from operations | $30.1 million | $25.0 million | Higher operating loss |
| Net loss | $8.6 million | $26.4 million | Improved by $17.8 million |
| Basic loss per share | $0.23 | $0.99 | Improved |
| Cash used in operating activities | $15.8 million | $23.0 million | Lower use by $7.2 million |
| Cash and cash equivalents | $15.5 million | $7.1 million | Up $8.5 million |
| Total liabilities | $17.9 million | $22.3 million | Down $4.4 million |
| Stockholders’ equity (deficit) | $(0.5) million | $(11.3) million | Improved but remained negative |
- The reduction in reported net loss was primarily driven by a $20.6 million decrease in the fair value of warrant liability and a $1.5 million gain from extinguishment of the Intrexon liability. These were largely non-operating or non-cash items.
- The company had an accumulated deficit of $216.8 million at December 31, 2018.
- Revenue recognition from the $10.0 million MEDINET upfront payment had not begun; the full amount remained recorded as deferred revenue because the arrangement was wholly unperformed.
- Debt was not material at year-end: the Silicon Valley Bank equipment loan was fully repaid in May 2018.
- Financing activities provided $25.4 million, principally from common-stock issuances. The October 2018 offering generated $17.0 million of gross proceeds before offering costs.
Material Changes Versus 2017
- The NeoCart Phase 3 trial outcome and FDA feedback fundamentally changed the company’s strategy from clinical development to strategic alternatives and cash preservation.
- Reported net loss declined substantially, but operating expenses increased because of a $4.3 million asset impairment and higher general and administrative costs.
- Cash increased because equity financings more than offset operating cash burn.
- Warrant liability declined from $14.7 million to $2.5 million, producing a $20.6 million fair-value gain in 2018.
- Property and equipment declined from $2.7 million to $0.1 million after the impairment charge associated with discontinuation of NeoCart.
- In December 2018, the company terminated its Intrexon collaboration and reduced an approximately $3.0 million accrued obligation to a $1.125 million liability, recording a $1.5 million gain.
- In October 2018, the company repriced 3.8 million stock options to $0.568 per share and cancelled certain performance-based options.
Guidance, Outlook, Risks and Unusual Items
- Management expected existing cash, cash equivalents and marketable securities to fund operations only into the middle of 2019, creating substantial doubt about the company’s ability to continue as a going concern.
- The independent auditor highlighted the going-concern uncertainty. At December 31, 2018, total liabilities exceeded total assets by approximately $0.5 million.
- January and March 2019 restructuring actions eliminated all but one employee, with key executives expected to continue as consultants. Expected first-quarter 2019 severance and related charges were approximately $1.4 million for the first restructuring and $2.2 million for the second.
- The company stated that there was no guarantee that a strategic transaction would be completed or that any cash or securities would be returned to stockholders. A bankruptcy, wind-down or liquidation could result in the common stock becoming worthless.
- In the first quarter of 2019, the company reduced the exercise prices of most 2016 warrants and all 2018 warrants to $0.01. The exercises generated approximately $0.1 million and $0.2 million of gross proceeds, respectively, but potentially increased share dilution.
- Nasdaq issued deficiency notices relating to the minimum $1.00 bid price and minimum $35 million market value of listed securities. The company faced compliance deadlines of April 15, 2019 and June 17, 2019, subject to available extensions and appeals.
- Management reported ineffective disclosure controls and internal control over financial reporting because of a material weakness involving highly complex or unusual transactions, including warrant valuation and the Intrexon termination accounting.
- The company had approximately $10.9 million of minimum remaining lease payments under non-cancellable operating leases at December 31, 2018, despite its cash-conservation and potential wind-down plans.
Most Important Facts to Verify
- Confirm that this filing belongs to Histogenics Corporation rather than Ocugen, Inc.
- Review the audited financial statements and going-concern disclosure, including the negative stockholders’ equity and projected cash runway into mid-2019.
- Assess the status and outcome of the strategic-alternatives process, including any sale, merger, liquidation or bankruptcy filing.
- Verify the extent of post-year-end restructuring, severance obligations, lease commitments and remaining contingent liabilities.
- Reconcile post-year-end warrant exercises, resulting share counts and potential dilution.
- Review Nasdaq listing compliance and any subsequent delisting, reverse-split or trading-market developments.
- Evaluate whether the MEDINET agreement remains active, whether the $10.0 million deferred revenue is recoverable or refundable, and whether any milestone or royalty value remains realistic after NeoCart discontinuation.
- Monitor remediation of the disclosed material weakness and the effect of any future accounting revisions involving warrant liabilities or unusual transactions.